Compare APT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | BTAI |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 43.7M |
| IPO Year | 1995 | 2018 |
| Metric | APT | BTAI |
|---|---|---|
| Price | $5.25 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 47.5K | ★ 483.7K |
| Earning Date | 03-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $59,096,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $265.60 |
| P/E Ratio | $15.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.06 | $1.17 |
| 52 Week High | $6.20 | $8.08 |
| Indicator | APT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 41.30 |
| Support Level | $4.96 | $1.36 |
| Resistance Level | $5.64 | $1.72 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 40.58 | 34.31 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.